SMAD4 TGF-β–independent function preconditions naive CD8+ T cells to prevent severe chronic intestinal inflammation
Ramdane Igalouzene, … , Julien C. Marie, Saïdi M’Homa Soudja
Ramdane Igalouzene, … , Julien C. Marie, Saïdi M’Homa Soudja
Published April 15, 2022
Citation Information: J Clin Invest. 2022;132(8):e151020. https://doi.org/10.1172/JCI151020.
View: Text | PDF
Research Article Gastroenterology Immunology

SMAD4 TGF-β–independent function preconditions naive CD8+ T cells to prevent severe chronic intestinal inflammation

Abstract

SMAD4, a mediator of TGF-β signaling, plays an important role in T cells to prevent inflammatory bowel disease (IBD). However, the precise mechanisms underlying this control remain elusive. Using both genetic and epigenetic approaches, we revealed an unexpected mechanism by which SMAD4 prevents naive CD8+ T cells from becoming pathogenic for the gut. Prior to the engagement of the TGF-β receptor, SMAD4 restrains the epigenetic, transcriptional, and functional landscape of the TGF-β signature in naive CD8+ T cells. Mechanistically, prior to TGF-β signaling, SMAD4 binds to promoters and enhancers of several TGF-β target genes, and by regulating histone deacetylation, suppresses their expression. Consequently, regardless of a TGF-β signal, SMAD4 limits the expression of TGF-β negative feedback loop genes, such as Smad7 and Ski, and likely conditions CD8+ T cells for the immunoregulatory effects of TGF-β. In addition, SMAD4 ablation conferred naive CD8+ T cells with both a superior survival capacity, by enhancing their response to IL-7, as well as an enhanced capacity to be retained within the intestinal epithelium, by promoting the expression of Itgae, which encodes the integrin CD103. Accumulation, epithelial retention, and escape from TGF-β control elicited chronic microbiota-driven CD8+ T cell activation in the gut. Hence, in a TGF-β–independent manner, SMAD4 imprints a program that preconditions naive CD8+ T cell fate, preventing IBD.

Authors

Ramdane Igalouzene, Hector Hernandez-Vargas, Nicolas Benech, Alexandre Guyennon, David Bauché, Célia Barrachina, Emeric Dubois, Julien C. Marie, Saïdi M’Homa Soudja

×

Figure 2

CD8αβ+ T cell depletion prevents intestinal inflammation upon SMAD4 deletion in T cells.

Options: View larger image (or click on image) Download as PowerPoint
CD8αβ+ T cell depletion prevents intestinal inflammation upon SMAD4 dele...
(A) Scheme of the in vivo CD8β+ and CD4+ T cell depletion. (B) Body weight on days 35–40 after reconstitution with WT or SKO BM cells and treatment with anti-CD8β or anti-CD4 depleting antibody (n = 5–20). (C) Representative pictures of colons and colon length measurement of BM-reconstituted mice, treated with anti-CD8β or anti-CD4 depleting antibody (n = 7–14). (D and E) Representative H&E staining of duodenum and colon sections (D) and histological damage score (E) of irradiated mice reconstituted with WT or SKO BM cells and treated with anti-CD8β or anti-CD4 depleting antibody (n = 3–4). Scale bars: 50 μm. Original magnification, ×20. Red arrows highlight crypt abscesses: yellow arrows highlight immune infiltrate, green arrows highlight crypt irregularity. All data represent at least 3 independent experiments and are presented as mean ± SD. Each symbol represents an individual mouse and n = 3 or more for each group. Data were analyzed by unpaired 1-way ANOVA followed by Tukey’s test. *P < 0.05; ****P < 0.0001. NS, not significant (P > 0.05).